Amit Bakshi
#323Chairman and Managing Director
52
Age
30y
Exp
18y
Tenure
8/10
Risk
🎓 not found · not found
📜 — · —
🏛️ None
CompensationTBP
Personality
7
Open
7
Cons
6
Extr
5
Agre
3
Neur
ERIS Lifescience
Healthcare · Mid Cap
High Growth · Founder-Centric
About
Amit Bakshi is the Chairman and Managing Director of ERIS Lifescience, a Mid Cap company in the Healthcare sector with a market cap of ₹18K Cr. A Visionary leader with 30 years of experience, he is known for intuition-driven decision-making and aggressive acquirer strategy. Has consistently demonstrated an aggressive M&A-led growth strategy to build a specialized chronic-therapy focused pharmaceutical portfolio.
FAQ
What is Amit Bakshi's leadership style?
Amit Bakshi is classified as a Visionary leader. He is intuition-driven in decision-making, with a category creator motivation and startup-speed pace of execution.
What is Amit Bakshi's educational background?
Amit Bakshi holds a not found from not found and a — from —.
Who is the CEO of ERIS Lifescience?
Amit Bakshi is the Chairman and Managing Director of ERIS Lifescience. He has been with the company for 18 years and in the current role for 18 years.
Leadership DNA
ArchetypeVisionary
MotivationCategory Creator
CrisisRevenue Hunter
DecisionIntuition-Driven
GrowthAggressive Acquirer
PeopleRelationship Led
InnovationFast-Follower
PaceStartup-Speed
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployerDemanding Machine
BrandTechnical-Expert
FocusMarket Expansion
OrientationDeep Specialist
Leadership Evidence
“Has consistently demonstrated an aggressive M&A-led growth strategy to build a specialized chronic-therapy focused pharmaceutical portfolio.”
⚡ Crisis●●●●○
Eris consistently prioritizes market share expansion in the chronic therapy segment even during challenging periods by launching new brands and expanding field force reach.
🎯 Motivation●●●●○
Bakshi built Eris by focusing on high-end, branded, patent-protected, and complex chronic therapies rather than competing in the commoditized generic volume market.
👥 People●●●○○
The company maintains a highly stable top management team with long tenures, reflecting a culture built on personal trust and deep industry relationships.
📈 Growth●●●●●
Eris has executed multiple strategic acquisitions including the purchase of brands from Glenmark, Strides, and the acquisition of Oaknet Healthcare to scale rapidly.
💡 Innovation●●●●○
Eris consistently focuses on high-growth, patent-expired therapy areas like chronic care, scaling through aggressive brand building rather than novel drug discovery.
🏃 Pace●●●●○
The company has demonstrated an aggressive acquisition-led strategy, rapidly integrating brands like Oaknet and Strides to scale its market footprint.
🌱 Purpose●●●○○
The company's strategic focus is heavily centered on maximizing shareholder value through M&A-led growth and high-margin specialty segments.
🏷️ Brand●●●●○
Eris is positioned as a specialist in complex chronic and sub-chronic therapies, relying on deep therapeutic knowledge to gain doctor trust.
🤝 Customer●●●●●
Eris operates a B2B2C model where it relies on its field force to influence doctors and medical professionals who prescribe their specialty drugs.
💼 Employer●●●○○
The company maintains a high-performance, sales-driven culture typical of the Indian pharma sector, characterized by aggressive growth targets and field-force intensity.
📋 Mandate
Following recent acquisitions, the company must focus on expanding its specialized portfolio and integrating new therapeutic segments.
🏢 Culture●●●●○
Strong influence of CMD Amit Bakshi; typical of rapidly scaled promoter-led pharma companies in India.
Financials
Revenue FY25₹3K Cr
PAT FY25₹352 Cr
Rev CAGR 5Y29.5%
OPM24.4%
NPM12.2%
ROE12.3%
ROCE12.4%
P/E41.8
Fwd P/E26.2
P/B5.8
D/E68.2
Promoter68%
Institutional21.9%
Mkt Cap₹18K Cr
Compensation
To Be Published
Data being verified from audited reports
